in ,

DLH to Help HHS Evaluate COVID-19 Treatment Alternatives, Develop Comm Tools

DLH Holdings
DLH Holdings
DLH Holdings
DLH Holdings

DLH Holdings has booked contracts and task orders to help the Department of Health and Human Services assess alternative treatment options for COVID-19 and effects of the novel coronavirus on chronic medical conditions.

The company said Tuesday it will also develop communication tools to support exchange of COVID-19-related data within the scientific community.

“As the National Institute for Allergy and Infectious Diseases continues to lead the national response to finding vaccines and therapeutics to combat this novel coronavirus pandemic, DLH will draw on its contract research organization (CRO) expertise, leveraging clinical research services to establish a platform to rapidly evaluate multiple therapeutic products," said Zach Parker, president and CEO of DLH.

Parker added that the company will recruit qualified patients and conduct clinical trials as part of efforts to help contain the pandemic.

DLH expects the generate $15M in incremental revenue from the recent awards.

ExecutiveBiz Logo

Sign Up Now! ExecutiveBiz provides you with Daily Updates and News Briefings about Contract Awards


Written by Nichols Martin

a staff writer at Executive Mosaic, produces articles on the federal government's technology and business interests. The coverage of these articles include government contracting, cybersecurity, information technology, health care and national security.

Carahsoft Brings CyberReef’s Mobile Security, Data Use Management Services to Government Market
Aerojet Rocketdyne
Aerojet Rocketdyne Furthers Propulsion System Test for DARPA Hypersonics Program